Summary

The global GLP-1 agonists weight loss drugs market is expanding at a remarkable pace as incretin-based medicines reshape how obesity is treated worldwide. Impressive weight reduction results, broader acceptance of obesity as a chronic condition requiring medical care, and strong consumer interest are fueling rapid prescription growth and prompting large investments in production capacity. The global GLP-1 agonists weight loss drugs market is expected to be valued at US$ 38.00 Billion in 2026 and is projected to reach US$ 147.62 Billion by 2033, growing at a CAGR of 21.4% between 2026 and 2033.

Market Insights:

GLP-1 receptor agonists replicate the action of a gut hormone that controls hunger, delays stomach emptying, and enhances insulin secretion, resulting in meaningful and lasting weight loss. Dual and triple receptor agonists acting on GIP and glucagon pathways are showing further improvements in weight reduction during clinical development. Pharmaceutical companies are advancing oral tablets and less frequent dosing schedules to improve convenience compared with weekly injections. Growing evidence of cardiovascular, renal, and metabolic benefits is strengthening the clinical case for these therapies. However, supply limitations, high prices, and reimbursement challenges continue to shape market access as producers expand capacity globally.

Drivers:

Rising obesity prevalence among adults and adolescents worldwide is the leading driver of market growth. Robust clinical evidence demonstrating significant weight loss and reduced cardiovascular events is encouraging wider prescribing by healthcare providers. New regulatory approvals for related conditions, including obstructive sleep apnea and cardiovascular risk reduction, are expanding the treatable population. Heightened public awareness through media coverage and digital health channels is increasing patient requests for these medicines. In addition, gradual improvements in insurance and employer coverage are enhancing affordability, while telehealth platforms are making consultation and prescription more convenient for patients.

Business Opportunity:

The development of oral small-molecule GLP-1 agonists presents a major opportunity, offering the potential for lower production costs and easier global distribution than injectable biologics. Next-generation multi-receptor agonists with stronger efficacy and better tolerability form a highly promising pipeline area. Patent expiries on earlier molecules are creating room for biosimilar and generic entrants, especially in cost-sensitive emerging markets. Research into therapies that preserve muscle mass during weight loss is gaining attention. Furthermore, combining medication with digital coaching, nutritional guidance, and remote monitoring can improve long-term results and generate new service revenue for pharmaceutical and digital health companies.

Region Analysis:

North America leads the global GLP-1 agonists weight loss drugs market, driven by high obesity rates, rapid prescriber uptake, premium pricing, and extensive access through retail, mail-order, and telehealth channels in the United States. Europe accounts for a considerable share as approvals broaden and health systems assess reimbursement for obesity therapies. Asia Pacific is projected to grow at the fastest rate, supported by increasing obesity prevalence, rising healthcare expenditure, domestic drug development, and the expected arrival of lower-cost versions in China, India, and Japan. Latin America is recording growing demand in Brazil and Mexico, and the Middle East & Africa is seeing fast adoption across Gulf nations.

Key Players:

• Novo Nordisk A/S
• Eli Lilly and Company
• Pfizer Inc.
• AstraZeneca plc
• Amgen Inc.
• Roche Holding AG
• Viking Therapeutics, Inc.
• Zealand Pharma A/S
• Boehringer Ingelheim International GmbH
• Structure Therapeutics Inc.

Segmentation:

By Drug Class

• Semaglutide-Based
• Tirzepatide-Based
• Others

By Route of Administration

• Injectable
• Oral

By Indication

• Obesity/Chronic Weight Management
• Type 2 Diabetes with Weight Management

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global GLP-1 Agonists Weight Loss Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
3.1. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
3.1.1. Semaglutide-Based
3.1.2. Tirzepatide-Based
3.1.3. Others
3.2. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
3.2.1. Injectable
3.2.2. Oral
3.3. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
3.3.1. Obesity/Chronic Weight Management
3.3.2. Type 2 Diabetes with Weight Management
3.4. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.4.1. North America
3.4.2. Europe
3.4.3. Asia Pacific
3.4.4. Latin America
3.4.5. Middle East & Africa
4. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
4.1. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
4.1.1. Semaglutide-Based
4.1.2. Tirzepatide-Based
4.1.3. Others
4.2. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
4.2.1. Injectable
4.2.2. Oral
4.3. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
4.3.1. Obesity/Chronic Weight Management
4.3.2. Type 2 Diabetes with Weight Management
4.4. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.4.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
4.4.2. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
4.4.3. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
4.4.4. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
4.4.5. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
4.4.6. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
4.5. BPS Analysis/Market Attractiveness Analysis
5. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
5.1. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
5.1.1. Semaglutide-Based
5.1.2. Tirzepatide-Based
5.1.3. Others
5.2. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
5.2.1. Injectable
5.2.2. Oral
5.3. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
5.3.1. Obesity/Chronic Weight Management
5.3.2. Type 2 Diabetes with Weight Management
5.4. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.4.1. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.2. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.3. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.4. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.5. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.6. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.7. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.8. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.9. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.10. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.11. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.12. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.13. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.14. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.15. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.16. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.17. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.18. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.4.19. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
5.4.20. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
5.4.21. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
5.5. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
6.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
6.1.1. Semaglutide-Based
6.1.2. Tirzepatide-Based
6.1.3. Others
6.2. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
6.2.1. Injectable
6.2.2. Oral
6.3. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
6.3.1. Obesity/Chronic Weight Management
6.3.2. Type 2 Diabetes with Weight Management
6.4. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.4.1. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.2. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.3. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.4.4. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.5. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.6. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.4.7. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.8. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.9. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.4.10. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.11. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.12. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.4.13. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.14. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.15. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.4.16. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
6.4.17. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
6.4.18. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
6.5. BPS Analysis/Market Attractiveness Analysis
7. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
7.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
7.1.1. Semaglutide-Based
7.1.2. Tirzepatide-Based
7.1.3. Others
7.2. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
7.2.1. Injectable
7.2.2. Oral
7.3. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
7.3.1. Obesity/Chronic Weight Management
7.3.2. Type 2 Diabetes with Weight Management
7.4. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.4.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
7.4.2. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
7.4.3. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
7.4.4. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
7.4.5. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
7.4.6. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
7.4.7. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
7.4.8. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
7.4.9. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
7.4.10. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
7.4.11. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
7.4.12. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
7.5. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033
8.1. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
8.1.1. Semaglutide-Based
8.1.2. Tirzepatide-Based
8.1.3. Others
8.2. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
8.2.1. Injectable
8.2.2. Oral
8.3. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
8.3.1. Obesity/Chronic Weight Management
8.3.2. Type 2 Diabetes with Weight Management
8.4. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.4.1. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
8.4.2. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
8.4.3. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
8.4.4. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
8.4.5. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
8.4.6. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
8.4.7. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
8.4.8. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
8.4.9. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
8.4.10. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
8.4.11. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
8.4.12. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
8.4.13. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
8.4.14. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
8.4.15. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
8.5. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Novo Nordisk A/S
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Eli Lilly and Company
9.4.3. Pfizer Inc.
9.4.4. AstraZeneca plc
9.4.5. Amgen Inc.
9.4.6. Roche Holding AG
9.4.7. Viking Therapeutics, Inc.
9.4.8. Zealand Pharma A/S
9.4.9. Boehringer Ingelheim International GmbH
9.4.10. Structure Therapeutics Inc.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations